Ramtace Side Effects

The safety profile of ramipril includes persistent dry cough and reactions due to hypotension. Serious adverse reactions include angioedema, hyperkalaemia, renal or hepatic impairment, pancreatitis, severe skin reactions and neutropenia/ agranulocytosis.
Cardiac disorders: Myocardial ischaemia including angina pectoris or myocardial infarction, tachycardia, arrhythmia, palpitations, oedema peripheral.
Blood and lymphatic system disorders: Eosinophilia, white blood cell count decreased (including neutropenia or agranulocytosis), red blood cell count decreased, haemoglobin decreased, platelet count decreased, bone marrow failure, pancytopenia, haemolytic anaemia.
Nervous system disorders: Headache, dizziness, vertigo, paraesthesia, ageusia, dysgeusia, tremor, balance disorder, cerebral ischaemia including ischaemic stroke and transient ischaemic attack, psychomotor skills impaired, burning sensation, parosmia.
Eye disorders: Visual disturbance including blurred vision, conjunctivitis.
Ear and labyrinth disorders: Hearing impaired, tinnitus.
Respiratory, thoracic and mediastinal disorders: Non-productive tickling cough, bronchitis, sinusitis, dyspnoea, bronchospasm including asthma aggravated, nasal congestion.
Gastrointestinal disorders: Gastrointestinal inflammation, digestive disturbances, abdominal discomfort, dyspepsia, diarrhoea, nausea, vomiting, pancreatitis (cases of fatal outcome have been very exceptionally reported with ACE inhibitors), pancreatic enzymes increased, small bowel angioedema, abdominal pain upper including gastritis, constipation, dry mouth, glossitis, aphtous stomatitis.
Renal and urinary disorders: Renal impairment including renal failure acute, urine output increased, worsening of a pre-existing proteinuria, blood urea increased, blood creatinine increased.
Skin and subcutaneous tissue disorders: Rash in particular maculopapular, angioedema; very exceptionally, the airway obstruction resulting from angioedema may have a fatal outcome; pruritus, hyperhidrosis, exfoliative dermatitis, urticaria, onycholysis, photosensitivity reaction, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, pemphigus, psoriasis aggravated, dermatitis psoriasiform, pemphigoid or lichenoid exanthema or enanthema, alopecia.
Musculoskeletal and connective tissue disorders: Muscle spasms, myalgia, arthralgia.
Metabolism and nutrition disorders: Blood potassium increased, anorexia, decreased appetite, blood sodium decreased.
Vascular disorders: Hypotension, orthostatic blood pressure decreased, syncope, flushing, vascular stenosis, hypoperfusion, vasculitis, Raynaud's phenomenon.
General disorders and administration site conditions: Chest pain, fatigue, pyrexia, asthenia.
Immune system disorders: Anaphylactic or anaphylactoid reactions, antinuclear antibody increased.
Hepatobiliary disorders: Hepatic enzymes and/or bilirubin conjugated increased, jaundice cholestatic, hepatocellular damage, acute hepatic failure, cholestatic or cytolytic hepatitis (fatal outcome has been very exceptional).
Reproductive system and breast disorders: Transient erectile impotence, libido decreased, gynaecomastia.
Psychiatric disorders: Depressed moods, anxiety, nervousness, restlessness, sleep disorder including somnolence, confusional state, disturbance in attention.